Introduction
Autologous and allogeneic hematopoietic stem cells (HSCs) mobilized into the peripheral blood (PB) have become a frequently used source of transplantable cells for the treatment of hematological malignancies and non-malignant disorders. 1 To mobilize HSC rapidly and efficiently, donors or patients are treated with G-CSF, which transiently releases HSC from the BM into the PB. [2] [3] [4] The number of HSC mobilized by G-CSF varies a lot between individual donors. 5 As up to 14% of autologous donors respond poorly to G-CSF, 6 better strategies for HSC mobilization are greatly desired. An approach that has already been introduced in clinical trials is to combine G-CSF with the CXCR-4 antagonist Plerixafor, which mobilizes HSCs more effectively, especially in heavily pretreated patients with non-Hodgkins lymphoma or multiple myeloma. 7 The Abs against the integrin very late Ag 4 (VLA-4)/ CD49d can mobilize long-term repopulating hematopoietic progenitors in preclinical models. 8, 9 Natalizumab (Tysabri, Biogen Idec, Cambridge, MA, USA) is the first a4 integrin antagonist in a new class of selective adhesion molecule inhibitors for the treatment of multiple sclerosis (MS). Natalizumab binds to a4 integrin on the surface of leukocytes, inhibiting their migration into the brain and thereby reducing inflammation. One major risk attributable to a4 integrin blockade has been the occurrence of cases with progressive multifocal leukoencephalopathy observed after natalizumab therapy. 10, 11 Recently, it has been reported that the number of circulating CD34 þ HSC markedly increases during natalizumab treatment in MS patients. 12, 13 These reports have raised great interest, because they have opened the prospect of examining CD49d blockade as a new mobilization strategy. Up to now, the phenotypes and functions of HSC mobilized with natalizumab and the effect on steady-state hematopoiesis in the BM have not been characterized in detail. Therefore, we have compared BM, PB and purified CD34 þ cells of MS patients after natalizumab treatment with BM and G-CSF-mobilized PB from healthy donors and also compared their post treatment profiles to PB of MS patients without natalizumab treatment. Our data show for the first time that continued administration of natalizumab also increases BM CD34 þ cells, and that CD34 þ cells mobilized into the PB by natalizumab have a different phenotype and migratory potential compared with G-CSF-mobilized CD34 þ HSC.
Materials and methods

Patients
Peripheral blood (PB-nat; n ¼ 8) and BM (BM-nat; n ¼ 4) of MS patients receiving natalizumab (Tysabri, Biogen Idec; three women, and five men with a median age of 31.5 years) were analyzed in this study. These patients, who had not responded to other immunomodulatory treatment, received 300 mg natalizumab i.v. at monthly intervals (median: 19 times; range: 7-25). PB and BM samples for immunophenotyping were taken 1 month after the last infusion of natalizumab just before the next scheduled infusion. In two patients, sequential measurements were performed before and 24 h after the first natalizumab administration. PB of 6 MS patients who did not have natalizumab therapy (PB-MS), PB of 11 G-CSF-stimulated healthy volunteers (PB-donor) and BM of 11 healthy donors (BM-donor) served as controls. Healthy donors received 7.5 mg/kg lenograstim (daily dose) subcutaneously over 5 days. In addition, three aphereses from G-CSFmobilized healthy donors (G-CSF HSC) and three from MS patients after natalizumab therapy (HSC-nat) were analyzed after CD34 þ cell selection. MS patients received natalizumab as a prescribed medication according to the label of the compound within the European Union. Written informed consent was obtained in all cases. The studies of CD34 þ HSC performed in vitro had been approved by the institutional review board of the University Hospital Dresden (EK263122004).
Flow cytometric immunophenotyping
Immunophenotyping was performed by four-color lysewash flow cytometry. Progenitor cells were identified using CD34-APC and CD45-PerCP5.5 (clone 581; clone 2D1; BD Biosciences, Heidelberg, Germany). Two further Abs, labelled with FITC or PE, were added for characterizing expression of the following adhesion molecules: CD11a/ CD18, which is a beta2 integrin, also called lymphocyte function-associated Ag-1 (clone G-25.2; BD Biosciences), L-selectin, and CD31, the plt endothelial cell adhesion molecule PECAM (clone DREG56; clone 1F11; BeckmanCoulter, Krefeld, Germany), plus heparan sulfate proteoglycan CD44 and integrin 4 CD49d (clone F10-44-2; clone 44H6; Biozol, Esching, Germany). The surface expression of the chemokine receptor CXCR-4/CD184 (clone 12G5; BD Biosciences) and the stem cell Ag CD133 (clone 293C3; Miltenyi Biotec, Bergisch Gladbach, Germany) were also evaluated. Stem and progenitor cells were selected by gating as CD34 þ CD45 dim cells with low side scatter. Whenever possible, 2000 target cells with approximately 500 000 events overall were registered. Fluorescence-minus-one controls for FITC and PE provided the threshold setting for adhesion molecule expression. All measurements were performed on a FACS Canto II flow cytometer equipped with three lasers (488 nm, 633 nm, and 405 nm) using FACS DiVa software. Percentages and mean fluorescence intensity were assessed. Mean fluorescence intensity was expressed as the ratio of the fluorescence intensity of Ab-positive cells and the fluorescence intensity of the respective isotype nonspecific control. Absolute counts of CD34 þ progenitor cells (per ml) were calculated by multiplying WBC counts measured by a hematology analyzer (Sysmex XE-2100, Norderstedt, Germany) with the respective percentages measured by FACS.
Purification of CD34 þ cells CD34 þ HSCs were purified from leukapheresis samples by attachment to magnetic beads conjugated with CD34 Ab, according to the manufacturer's instructions (MACS, Miltenyi Biotec). The purities as assessed by flow cytometry for the HSC fraction derived from samples mobilized by G-CSF were 95.6 ± 0.9% and for natalizumab 91.2 ± 0.6%. Trypan blue exclusion confirmed 496% viability in every sample. After CD34 þ purification, cells were labelled with the following Abs: CD34-APC (clone AC136, Miltenyi Biotec), CD133-PE (clone AC133, Miltenyi Biotec) and CXCR-4 PE (clone 12G5, BD Biosciences).
CFU-C assay in unmanipulated leukapheresis samples
In all, 1 Â 10 5 cells from each leukapheresis sample were plated in 35-mm Petri dishes (Greiner, Frickenhausen, Germany) in a total volume of 1 ml standard methylcellulose medium with recombinant cytokines (MethoCult GF þ H4435; Stem Cell Technologies, Vancouver, Canada) in triplicate. All cultures were incubated at 37 1C in fully humidified air with 5% CO 2 . After 14 days, erythroid bursts (BFU-E), myeloid colonies (CFU-GM), and mixed-cell colonies (CFU-GEMM) were scored with an inverted light microscope (Carl Zeiss, Jena, Germany). Colonies were defined as clusters consisting of X40 cells. The frequency of colonies is provided per 1000 CD34 þ cells inserted.
Transwell migration assay A 600 ml aliquot of serum-free medium containing 300 ng/ ml stromal cell-derived factor-1 (SDF-1; R&D Systems, Minneapolis, MN, USA) was added to the lower chamber of a 5 mm 24-well polycarbonate transwell culture dish (Corning Costar Corporation, Cambridge, MA, USA). Subsequently, 2 Â 10 5 purified CD34 þ cells suspended in 0.1-ml medium were added to the upper chamber and allowed to migrate for 4 h at 37 1C. Cells that had migrated into the lower chamber were collected and counted. Spontaneous migration without SDF-1 addition was estimated as a control.
PCR analysis
After CD34 þ cells had been separated, total RNA was isolated from purified MS CD34 þ cells and G-CSFmobilized CD34 þ cells using Trizol (Invitrogen, Carlsbad, CA, USA) and transcribed into cDNAs with oligo dT.
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A quantitative TaqMan real-time PCR was performed for cyclin-dependent kinase inhibitor 1A (21), cell cycle regulator-G0/G1switch (G0S2), and matrix metallopeptidase 9 (MMP9). The housekeeping gene GAPDH was used as control. All primers were purchased from Applied Biosystems (Foster City, CA, USA). For calculating relative gene expression, the 2 ÀDDCT formula was used, where DDCT ¼ (CT, target-CT, GAPDH) MS CD34 þ cells-(CT, target-CT, GAPDH) G-CSF-mobilized CD34 þ cells.
Proliferation assay
Purified CD34 þ cells were suspended in CellGros SCGM medium (CellGenix, Freiburg, Germany) with 150 ng/ml fetal liver tyrosine kinase-3 ligand, 150 ng/ml SCF (both from Biosource, Camarillo, CA, USA), and 50 ng/ml IL-3 (Miltenyi Biotec). HSC suspensions were plated at 4 Â 10 4 cells/well in six-well plates at 37 1C and 5% CO 2 . The number of total nucleated cells was counted on days 1, 3, 5 and 7 by Trypan Blue (vitality more than 95%).
Statistics
Statistical analyses were performed using GraphPad Prism 4 (GraphPad Software, San Diego, CA, USA). Descriptive statistics provide the median and ranges for most quantitative parameters. All continuous variables were compared using the nonparametric Mann-Whitney test. Differences were assessed as significant if the P-value was at least o0.05. All tests were performed two-sided.
Results
Frequency of CD34 þ progenitor cells
The CD34 þ cell concentration was significantly higher in the BM of MS patients receiving natalizumab compared with values measured in healthy volunteers donating BM donors during the same period of time (BM-donor; P ¼ 0.005). Interestingly, the frequency of CD34 þ cells in the BM was directly correlated with the number of natalizumab infusions with 617/ml after 15 infusions, 1342/ml after 21 infusions, 1350/ml after 23 infusions and 2250/ml after 32 cycles, respectively.
As previously shown, an elevated CD34 þ count was also detectable in PB from MS patients after repetitive natalizumab therapy (PB-nat) vs PB from MS patients without natalizumab, whereas the CD34 þ counts of the latter group were comparable to those of steady-state PB in unstimulated healthy donors (Figure 1 ).
Repeated measurements, carried out before and up to 4 days after the first administration of natalizumab in two patients, revealed the maximum CD34 þ absolute counts on day 4 (4/ml and 8/ml, respectively). Almost all adhesion molecules were downregulated after the first natalizumab administration. The blocking of VLA-4 through natalizumab was reflected as a decrease in mean VLA-4 mean fluorescence intensity from 4837 before treatment to 3089 after 72 h.
Differences in adhesion molecule and CD133 expression
The expression (percentage and/or mean fluorescence intensity) of most of the tested Ags (L-selectin, Pecam, CD44, lymphocyte function-associated Ag-1) was lower in both BM and PB of MS patients treated with natalizumab compared with healthy donors (Figures 2a-c) . Remarkably, CD133 expression on CD34 þ cells was also clearly lower in the BM as well as in PB of natalizumab-treated patients compared with healthy donors (BM-donor and PB-donor) (Figures 2a-c) .
Subpopulations in purified CD34 þ cells Besides BM and mobilized PB from MS patients after natalizumab, purified CD34 þ cells from apheresis samples CD49d blockade and hematopoietic function D Jing et al (HSC-nat) also expressed the primitive hematopoietic Ag CD133 less than the G-CSF-mobilized control cells (G-CSF HSC) did. However, no significant differences were observed in the CD34 þ CD38-compartment (data not shown). The expression of CXCR-4 (CD184) on CD34 þ cells from natalizumab-treated patients was significantly higher than on G-CSF-mobilized CD34 þ cells from healthy controls (43.9% (range, 42.3-52.9%) vs 15.1% (range, 7.8-17.8%), Po0.05, Figure 3b ). Representative contour plots are shown in Figure 3a .
Transwell migration assay
The increased expression of CXCR-4, as described above, was associated with a significantly better migration of CD34 þ cells from patients receiving natalizumab compared with G-CSF-mobilized CD34 þ cells measured 4 h after establishing a chemotactic stimulus (SDF-1) (13.4% (range, 12.2-17.1%) vs 6.1% (range, 4.9-7.4%), Po0.05, Figure 3c ).
mRNA expression
In our study, MMP9 mRNA was significantly diminished in natalizumab-mobilized CD34 þ cells whereas p21, a negative regulator of cell cycle, was significantly upregulated in CD34 þ cells mobilized by natalizumab (2.15-fold (range, 1.62-to 2.74-fold)). Correspondingly, the mRNA level of G0S2, a gene involved in cell cycle progression was decreased ( Figure 4 ).
Ex vivo expansion and clonogenicity
The proliferation capacity of CD34 þ selected cells derived from leukapheresis products after 7 days of in vitro culture is shown in Figure 5a . The absolute cell numbers were not significantly different after 7 days of culture in vitro. Consistent with the lower frequency of CD34 þ cells in the PB of natalizumab-treated patients (Figure 1 ), the absolute number of BFU-E and CFU-GM contained in leukapheresis samples was lower than in G-CSF-mobilized products. But still, the frequency of colonies per 1000 CD34 þ cells was comparable (Figure 5b ). Consistent with previous reports, BFU-E prevailed in HSC-nat (89.2% (range, 81.1-90.9%)) whereas the percentage of BFU-E (46.7% (range, 35.5-54.3%)) was similar to the granulocytemacrophage compartment (52.7% (range, 44-64.5%)) in G-CSF HSC (Figure 5b ). This strongly suggests that the chronic inflammatory condition has been invalidated by the negligible CD34 þ counts in MS patients not treated with natalizumab, who served as a controls in our series and in the two previous reports. [12] [13] [14] At present, we would not wish to exclude the possibility that the downregulation of adhesion molecules on CD34 þ cells, as confirmed in the phenotypic analysis, makes more CD34 þ cells occur in the aspirate simply because they are less adhesive and physically easier to dislocate. This hypothesis has already been suggested by Craddock et al. 9 They argued against the induction of proliferation by VLA4 blockade alone but suggested that secondary stimuli-like growth factor/ cytokine signaling are required to synergize with integrin blockade. As we have only analyzed CD34 þ cells as a mixture of stem and progenitor cells and did not distinguish between lineage-negative and positive or even CD34-negative stem cells, we can not exclude that CD49d expression may be different at the various stem and progenitor cell levels. In addition, a possible influence of CD49d blockade on the phenotype of stem and progenitor cells could be a possible mechanism involved. The heterogeneity of populations under investigation in our study may also explain the difference in mRNA levels of genes involved in cell cycle control (p21, G0S2) and matrix processing (MMP9).
The SDF-1/CXCR-4 chemokine axis is of major relevance for the migration and location of hematopoietic stem and progenitor cells. 15 HSC have been shown to localize nearby stromal cells expressing high levels of SDF-1. 16 But still, HSC lacking CXCR-4 are able to home and engraft back into the BM, although with a lower efficiency. 17 This supports the hypothesis that the additional interaction between HSC and stromal cells by the various integrins is highly important for the homing and retention of HSC in the BM stem cell niche. 18 By disrupting HSC retention and adhesion, both G-CSF and natalizumab promote egress of HSC into the PB. Our present results show that natalizumab mobilizes HSC with a higher CXCR-4 expression but lower expression of adhesion molecules (L-selectin, Pecam-1, lymphocyte functionassociated Ag-1 and CD44) when compared with CD34 þ cells mobilized by G-CSF. This is in line with previously published data suggesting that CXCR-4 expression on HSC and SDF-1 levels in BM are reduced after G-CSF administration. 19 Whether the difference in adhesion molecule expression on CD34 þ cells mobilized with natalizumab reflects a stochastic release of cells with lower CD49d blockade and hematopoietic function D Jing et al adhesion molecule expression or is related to the differentiation status remains to be analyzed. 20 The differences in surface molecule expression also reflect the alternative mechanisms involved in HSC mobilization. As the SDF-1/CXCR-4 axis has a separate essential role in HSC survival and repopulation in vivo and natalizumab induces HSC mobilization without interacting with SDF1 signaling, 21 CD49d blockade should be effective when used in combination with G-CSF. This synergism had previously been described in a preclinical model by Craddock et al.
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The lower expression of MMP9 in purified CD34 þ cells derived from apheresis products mobilized by natalizumab suggests that they resemble more steady-state BM CD34 þ cells, which have been shown to express MMP9 at lower levels compared with PB CD34 þ cells with or without G-CSF administration. 22 Consistent with the upregulation of CXCR-4, CD34 þ cells mobilized by natalizumab were better at migration in a chemokine-driven transwell assay. Although an increased migratory activity could predict for a more effective homing of HSC, animal models have shown for other mobilization strategies that decreased in vitro cell migration may still be associated with excellent in vivo engraftment. 23 Our observation contrasts with a recent report in which a reduced migratory capacity of CFU-C in patients receiving natalizumab was reported. The reported difference may be due to the fact that we analyzed CD34 þ selected cells derived from leukapheresis samples whereas Bonig et al. 13 analyzed unmanipulated PB. Possibly, the mechanical stress induced by leukapheresis and immunomagnetic selection may effect on the migratory activity of CD34 þ cells.
The downregulation of prominin-1/CD133, a ubiquitous marker of both neural and hematopoietic stem/progenitor cells, argues that natalizumab mobilizes a compartment that is beyond multipotential commitment, allowing that CD133 þ expression has been linked with long-term repopulating potential in vivo. 24, 25 The predominance of erythroid progenitors in the leukapheresis samples that we mobilized with natalizumab is in line with our own evidence that the CD34 þ CD133-fraction contains a significantly higher proportion of erythroid BFU-E, whereas most of the leukocyte CFU-GM are concentrated in the CD34 þ CD133 þ cells. 26 A predominance of erythroid progenitors after VLA-4 blockade has been described in the literature. 8 This may be explained by a differential expression of adhesion molecules on erythroid vs myeloid-macrophage progenitors.
In summary, disrupting the integrin-based interaction between HSC and their niche may provide a complementary strategy for their mobilization. Although the long half-life of natalizumab presently precludes its use in patients scheduled for autologous transplantation or healthy donors, selective antagonists of CD49d have been developed. Very recent preclinical studies suggest that these small molecules can be successfully combined with G-CSF or SDF-1/CXCR-4 blockade to dramatically increase the amount of mobilized hematopoietic stem and progenitor cells. 27 Further in vivo studies and clinical trials to evaluate the repopulating capacity of HSC mobilized by combined regimens incorporating CD49d blockade are recommended.
